Genentech reinvested approximately 21 percent of its operating revenues on a GAAP basis into research and development in 2007 — significantly more than the pharmaceutical industry average. To balance resource use with the strongest likelihood of success, Genentech continuously evaluates its pipeline products in order to determine which are the most promising projects to move through the many phases of clinical testing.
Genentech's development pipeline continues to grow, now numbering more than 100 projects in the following therapeutic focus areas: oncology, immunology, disorders of tissue growth and repair, and neuroscience. The pipeline includes both breakthrough innovations and potential new indications for existing, well-understood products that may fight more than one disease or more than one form of a disease.
Please refer to the product/project links provided below for detailed information regarding the development status of a project.
| Awaiting FDA Action | |
| Avastin® |
First-line metastatic renal cell carcinoma |
| Rituxan® |
Rheumatoid arthritis DMARD-inadequate responders |
| FDA Submission Preparation | |
| Avastin |
Relapsed glioblastoma multiforme |
| Xolair® |
Pediatric asthma |
| Phase III | |
| Avastin |
Adjuvant colon cancer Adjuvant HER2-negative breast cancer Adjuvant HER2-positive breast cancer Adjuvant non-small cell lung cancer Diffuse large B-cell lymphoma First-line advanced gastric cancer First-line HER2-negative metastatic breast cancer First-line HER2-positive metastatic breast cancer First-line metastatic ovarian cancer Gastrointestinal stromal tumors High risk carcinoid Hormone refractory prostate cancer Newly diagnosed glioblastoma multiforme1 Metastatic head and neck cancer1 Relapsed platinum-sensitive ovarian cancer Second-line metastatic breast cancer |
| Avastin +/- Tarceva® |
First-line metastatic, non-squamous, non-small cell lung cancer |
| Herceptin® |
Adjuvant HER2-positive breast cancer (HERA 2-year) |
| Lucentis® |
Diabetic macular edema Retinal vein occlusion |
| Ocrelizumab (2nd Generation Anti-CD20) | Lupus nephritis Rheumatoid arthritis |
| Pertuzumab |
First-line HER2-positive metastatic breast cancer |
| Rituxan Hematology/Oncology |
Follicular non-Hodgkin's lymphoma Relapsed chronic lymphocytic leukemia |
| Rituxan Immunology |
Active rheumatoid arthritis ANCA-associated vasculitis Lupus nephritis |
| Tarceva |
Adjuvant non-small cell lung cancer First-line metastatic non-small cell lung cancer |
| TNKase® |
Central venous catheter clearance Hemodialysis catheter clearance |
| Trastuzumab-DM1 |
Second-line HER2-positive metastatic breast cancer1 |
| Xolair |
Asthma |
| Phase II | |
| ABT-869 |
Advanced renal cell carcinoma Hepatocellular carcinoma Metastatic breast cancer Metastatic colorectal cancer1 Metastatic non-small cell lung cancer |
| Apomab |
Non-Hodgkin's lymphoma Non-small cell lung cancer |
| Avastin |
Extensive small cell lung cancer Non-squamous, non-small cell lung cancer with previously treated CNS metastases Relapsed multiple myeloma |
| Dacetuzumab (Anti-CD40) | Diffuse large B-cell lymphoma |
| Hedgehog Inhibitor |
Advanced basal cell carcinoma1 First-line metastatic colorectal cancer Ovarian cancer1 |
| MetMAb |
Non-small cell lung cancer1 |
| Ocrelizumab (2nd Generation Anti-CD20) |
Relapsing remitting multiple sclerosis |
| Pertuzumab |
Non-small cell lung cancer1 Ovarian cancer |
| Raptiva® | Renal transplantation1 |
| rhApo2L/TRAIL |
Non-Hodgkin's lymphoma Non-small cell lung cancer |
| Trastuzumab-DM1 |
First-line HER2-positive metastatic breast cancer Second-line HER2-positive metastatic breast cancer Third-line HER2-positive metastatic breast cancer |
| Xolair |
Chronic idiopathic urticaria1 |
| Phase I | |
| 3rd Generation Anti-CD20 |
Chronic lymphocytic leukemia Non-Hodgkin's lymphoma |
| ABT-263 |
Chronic lymphocytic leukemia Lymphoid malignancies Small cell lung cancer |
| ABT-869 |
Non-small cell lung cancer1 |
| Anti-Abeta |
Alzheimer's Disease |
| Anti-CD4 |
Rheumatoid arthritis |
| Anti-IL13 | Asthma |
| Anti-oxLDL | Secondary prevention of cardiovascular events |
| Apomab |
Colorectal cancer |
| Dacetuzumab (Anti-CD40) |
Diffuse large B-cell lymphoma Multiple myeloma Non-Hodgkin's lymphoma |
| GA101 |
Hematologic malignancies |
| huMAb OX40L | Asthma |
| IAP Antagonist | Cancer |
| MEK Inhibitor | Cancer |
| New Molecular Entity | Autoimmune disease |
| New Molecular Entity | Cancer |
| New Molecular Entity (ADC) | Cancer |
| PI3 Kinase Inhibitor | Cancer |
| rhApo2L/TRAIL | Colorectal cancer |
| rhuMAb Beta7 | Ulcerative colitis |
| rhuMAb IFNalpha | Systemic lupus erythematosus |
| Trastuzumab-DM1 + Pertuzumab | HER2-positive metastatic breast cancer1 |
Information updated October 2008
ADC = Antibody Drug Conjugate; ANCA = Anti-neutrophilic Cytoplasmic Antibodies;
CNS = Central Nervous System; DMARD = Disease-modifying Anti-rheumatic Drugs.